BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mendor's Mendor Balance® Receives CE Mark


6/18/2013 6:46:33 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Mendor Announces CE Marking for its Diabetes Management Platform

ESPOO, Finland, June 18, 2013 /PRNewswire/ -- Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance®. This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry.

Mendor Balance enables people living with diabetes to effortlessly share their blood glucose monitoring results with their caregiver from most glucose meters in the market today. Balance provides professionals with a set of tools to efficiently manage a clinic full of patients, with a future pipeline of real-life decision support protocols.

CE Mark Considered an Important Milestone for Treatment Individualization

The IVD (in vitro diagnostic) products have a clearly defined regulatory environment which is currently not common practice in software development designed to support diabetes management. Mendor's passionate team has been working extremely hard and built a product that meets all the regulatory specifications, now realized in the form of CE marking of Mendor Balance.

"I am very proud of our skillful software and clinical team for enabling the CE mark for Mendor Balance platform. This is the first CE marked meter agnostic platform in EU for storing and sharing blood glucose data. CE mark for Mendor Balance is an important step towards scalable and automated blood glucose analysis and decision support system, which are necessary features for blood glucose profiling and treatment individualization", states Antti Virkamäki, Endocrinologist and the Medical Director of Mendor.

Built to Scale Up and Adapt to Real-Life Diabetes Management

Diabetes is a major global health challenge. Mendor Balance is designed to give a new tool set for tackling escalating costs and ever scarcer resources. Mendor is currently running a number of patient trials, where the tools for blood glucose profiling are validated and the platform is fine-tuned for real-life clinical practice.

"I am very happy that we have come this far with Mendor Balance. Balance is an integral part of the future vision of Mendor in revolutionizing diabetes treatment with better glucose monitoring and data analysis. Big thanks and hats off to the awesome team who makes all this possible!", said Mendor's CEO and co-founder, Kristian Ranta

Media Contact:

Sanna Usva -Mgmt Assistant

Tel: +358-9-315-77-300

E-mail: info@mendor.com

Images available on request. For more information, visit: http://www.mendor.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Mendor
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES